Literature DB >> 9735503

[Distribution of bone metastases of cancers. A scintigraphic study of 376 cases].

D Bontoux1, F Plazanet, I Azais.   

Abstract

Technetium 99m methylene bisphosphonate bone scans of 376 patients with cancers of breast, prostate, lung, kidney, colon, and bladder and ENT cancer were reviewed, and the distribution of skeletal metastases was analyzed. Differences were not significant for rank order of metastatic involvement in 9 selected regions in any cancer, but the breast carcinoma. Patients with breast cancer had less pelvis and more skull involvement. The rate of skull metastases was significantly higher in breast cancer than in prostatic (p < 0.001), lung (p < 0.01) and kidney (p < 0.05) cancers. These results are weakly demonstrative of a role of the vertebral veins in hematogenous spread of breast and prostate cancer. The hypothesis is proposed that this pattern of dissemination, which is suggested by experimental and clinical features, is poorly perceptible in the distribution pattern of skeletal metastases because of the concurrent arterial spread of breast and prostatic tumors cells, which is likely preponderant.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9735503

Source DB:  PubMed          Journal:  Bull Acad Natl Med        ISSN: 0001-4079            Impact factor:   0.144


  3 in total

1.  Unusual case of skull metastasis secondary to pancreatic adenocarcinoma.

Authors:  Volkan M Aydin; Melih Cekinmez; Osman Kizilkilic; Fazilet Kayaselcuk; Orhan Sen; Nur Altinors
Journal:  Pathol Oncol Res       Date:  2005-09-29       Impact factor: 3.201

2.  Neurosurgical treatment of breast cancer metastases to the neurocranium.

Authors:  Andreas M Stark
Journal:  Patholog Res Int       Date:  2010-12-16

3.  Incidental finding of metastatic prostatic adenocarcinoma of frontotemporal bone presenting as subdual hematoma: A case report and review of literature.

Authors:  Kuang-Ting Liu; Yueh-Ching Chang; Junn-Liang Chang
Journal:  Ann Med Surg (Lond)       Date:  2021-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.